Imatinib for the adjuvant treatment of gastrointestinal stromal tumours

  • Technology appraisal guidance
  • TA326
  • Published: 
Download guidance (PDF)

1 Guidance

This guidance replaces Imatinib for the adjuvant treatment of gastrointestinal stromal tumours (NICE technology appraisal guidance 196 issued in August 2010). See about this guidance for more information

1.1 Imatinib is recommended as an option as adjuvant treatment for up to 3 years for adults who are at high risk of relapse after surgery for KIT (CD117)‑positive gastrointestinal stromal tumours, as defined by the Miettinen 2006 criteria[1] (based on tumour size, location and mitotic rate).

1.2 People currently receiving treatment initiated within the NHS with imatinib that is not recommended for them by NICE in this guidance should be able to continue treatment until they and their NHS clinician consider it appropriate to stop.


[1] Miettinen M, Lasota J (2006) Gastrointestinal stromal tumours: review on morphology, molecular pathology, prognosis, and differential diagnosis. Archives of Pathology & Laboratory Medicine 130:1466–78

  • National Institute for Health and Care Excellence (NICE)